Table 2

Associations between TGN levels and inhibition of the production of ATI (N=100)

Adjustment	Exposure categories	OR (95% CI)	P value
None	6-TGN 235–450 pmol/8×10⁸ erythrocytes vs monotherapy	9.9 (3.3 to 29.4)	<0.001
	6-TGN outside of range vs monotherapy	1.3 (0.4 to 3.8)	0.6
	6-TGN 235–450 pmol/8×10⁸ erythrocytes vs 6-TGN outside of range	7.6 (2.2 to 26.3)	0.001
Minimally adjusted*	6-TGN 235–450 pmol/8×10⁸ erythrocytes vs monotherapy	11.2 (3.6 to 34.9)	<0.001
	6-TGN outside of range vs monotherapy	1.5 (0.5 to 4.5)	0.5
	6-TGN 235–450 pmol/8×10⁸ erythrocytes vs 6-TGN outside of range	8.0 (2.2 to 29.7)	0.002
Fully adjusted†	6-TGN 235–450 pmol/8×10⁸ erythrocytes vs monotherapy	12.9 (3.8 to 43.0)	<0.001
Fully adjusted†	6-TGN outside of range vs monotherapy	1.7 (0.5 to 5.3)	0.4
Additionally adjusted average drug level AU/mL‡	6-TGN 235–450 pmol/8×10⁸ erythrocytes vs monotherapy	12.2 (3.5 to 42.1)	<0.001
	6-TGN outside of range vs monotherapy	1.5 (0.5 to 5.0)	0.5
	6-TGN 235–450 pmol/8×10⁸ erythrocytes vs 6-TGN outside of range	11.4 (2.2 to 59.2)	0.004

*Adjusted for gender and age only.
†Adjusted for gender, age, weight, diagnosis, smoking status, duration of disease and time on infliximab.
‡Adjusted for gender, age, weight, diagnosis, smoking status, duration of disease and time on infliximab and average infliximab drug level.
TGN, thioguanine.